Second REUMAVID Survey08 February 2021 NRAS are pleased along with Arthritis Action and NASS to be supporting this European study into the impact of COVID19 pandemic on people living with Rheumatic diseases. The survey will take approximately 30 minutes to complete. Take part in the survey This study is promoted by the National Axial Spondyloarthritis Society (NASS), the National Rheumatoid Arthritis Society (NRAS), and Arthritis Action, and conducted by the Health & Territory Research (HTR) of the University of Seville, Spain with the support of Novartis Pharma AG. The REUMAVID study is being conducted simultaneously in seven European countries (Cyprus, France, Greece, Italy, Portugal, Spain and the United Kingdom) in order to better understand the effects of COVID-19 on people living with rheumatic diseases by providing an international perspective. The first phase of the REUMAVID study took place between April-July 2020 and we would like to thank the 1,800 patients who participated as the results are being widely disseminated to advocate for the needs of patients with rheumatic diseases during this time. Your contribution to this second survey will help to design solutions that will help improve the well-being and quality of life of people living with rheumatic diseases once this current pandemic is over or in the event it extends for a longer period of time. The current survey is a comprehensive questionnaire, which requests information on personal, family, social, health and clinical habits and will take you between 25 and 30 minutes to complete. Your effort in completing the survey will not directly affect your care, as your answers will not reach your responsible physician. Your participation is voluntary and will not involve any additional costs or financial compensation.